Loading
Leads iStopMM, which screened most of Iceland's adults for myeloma precursors to test whether early detection helps.
Sigurdur Kristinsson (University of Iceland) leads iStopMM, the nationwide study that invited every Icelander over 40 to be screened for monoclonal gammopathy and randomised those found to have MGUS to different follow-up strategies, the first population-based test of whether screening for a myeloma precursor improves outcomes. The study has already refined MGUS prevalence and progression estimates and identified smouldering myeloma in the population.
| Title | Journal | Year |
|---|---|---|
| Screening for monoclonal gammopathy of undetermined significance: a population-based randomized clinical trial (iStopMM): first results | Blood Cancer Journal | 2021 |
| Prevalence of smoldering multiple myeloma based on nationwide screening | Nature Medicine | 2023 |
Shares Blood cancer journal, Multiple myeloma.
Shares the tags screening, epidemiology.
Shares the tags screening, epidemiology.
Shares the tags screening, epidemiology.
Shares iStopMM, Multiple myeloma.
Shares Multiple myeloma and the tag myeloma.
Shares Multiple myeloma and the tag myeloma.
Shares Multiple myeloma and the tag myeloma.